Pharmatel Pty Ltd was founded in 1985 and in 2004, the company formed a joint venture with Fresenius Kabi. In 2007, Pharmatel Fresenius Kabi became a fully owned subsidiary of Fresenius Kabi and in January 2010, the Company changed its name to Fresenius Kabi.
The Hirsch Pharmacy is opened in Frankfurt, Germany. The Fresenius family assumes ownership in the 18th century.
The pharmacist and proprietor of the Hirsch Pharmacy, Dr. Eduard Fresenius, founds the pharmaceutical company Dr. E. Fresenius.
Its main products are pharmaceutical specialities such as injection solutions, serologic reagents and Bormelin nasal ointment.
The manufacturing company is separated from the Hirsch Pharmacy and moves to Bad Homburg. Dr. Fresenius devotes more and more time to the company, which grows to around 400 employees.
Fresenius starts to sell dialysis machines and dialyser manufactured for various foreign companies and gains substantial market shares.
Introduction of a novel amino acid solution achieving a decisive breakthrough in parenteral nutrition therapy. Introduction of an innovative volume replacement solution (hydroxyethyl starch solution – HES) in the field of fluid therapy/blood substitution.
Fresenius starts to manufacture infusion solutions and medical disposables in St. Wendel, Saarland.
The first ready-to-use tube feed Fresubin® is introduced.
Introduction of HAES-steril®, a further development of the hydroxyethyl starch solution with which Fresenius sets worldwide standards in volume therapy.
Establishment of the home care concept by which patients who have to be fed enterally (intake of nutrients involving the gastro-intestinal tract) can be cared for at home. At the same time the enteral nutrition range is expanded.
Pharmatel founded by well known Australian pharmacist George Shortis. The Company quickly becomes an Australian market leader in bowel preparation and develops a strong reputation for its high level of services.
The Fresenius developed Aminomix® Two-Chamber-Bag for parenteral nutrition is launched.
Pharmatel commences compounding aseptic drugs for Australian hospitals, with a focus on oncology products in Sydney.
Launch of Supportan®, a tube feed for enteral nutrition in oncology.
Laying of the cornerstone of the innovative infusion solution plant in Friedberg (Hessen).
Introduction of the world’s first dipeptide solution for parenteral nutrition. Inauguration of the state-of-the-art infusions solutions plant (Friedberg, Hesse), the most modern one in Europe.
Fresenius Kabi is formed by combining Fresenius Group's Pharma division with the infusion solution business acquired from Pharmacia & Upjohn (Kabi). The new company is Europe's leader in the field of nutrition and infusion therapy, offering a comprehensive product and service portfolio worldwide for hospitals and patients at home.
Launch of a new generation of hydroxyethyl starch for volume therapy.
Fresenius Kabi accelerates its worldwide business expansion by opening up new growth markets in Asia, Africa and Latin America.
Pharmatel opens a TGA (Therapeutic Goods Administration) licensed compounding site in Melbourne, enhancing the company's ability to service the market.
Fresenius Kabi strengthens its market positions with acquisitions in South Africa and Czech Republic as well as with a joint venture in Australia.
Pharmatel Fresenius Kabi Pty Ltd is formed by a joint venture between Pharmatel Pty Ltd and Fresenius Kabi, allowing Pharmatel Fresenius Kabi to offer a greater range of nutrition products to the Australian and New Zealand markets.
Pharmatel Fresenius Kabi launches Kabiven®, a 3-chamber all-in-one complete parenteral nutrition product is launched onto the Australian market.
Colazide®, a new treatment for ulcerative colitis, is first registered in Australia.
Expansion of the I.V. drug portfolio via acquisition of the Portuguese pharmaceutical company Labesfal.
Fresenius Kabi strengthens product portfolio and production network of medical devices through the acquisition of the business of Clinico.
Pharmatel Fresenius Kabi launches the Fresenius Kabi range of enteral nutrition and infusion technology devices onto the Australian market, and expands the range of parenteral nutrition products that are available.
Acquisition of Argentinean pharmaceutical company Filaxis: Expansion of I.V. drug portfolio.
Pharmatel Fresenius Kabi launches Voluven® into Australia, an innovative product for volume therapy.
Fresenius Kabi strengthens business activities through acquisitions.
Blood volume replacement: Acquisition of blood volume replacement business of Japanese pharmaceutical company Kyorin
I.V. Drugs: Acquisition of the Chilean company Laboratorio Sanderson and the Italian company Ribbon
Clinical Nutrition: Acquisition of the enteral nutrition businesses from Nestlé in France and Spain.
Fresenius Kabi grows its IV generics business and expands into oncology drugs with the Dabur Pharma acquisition.
Fresenius Kabi enters the North American pharmaceuticals market and becomes a globally leading supplier in the field of intravenously administered generic drugs via the acquisition of the U.S. based APP Pharmaceuticals.
Pharmatel Fresenius Kabi achieves ISO9001:2000 accreditation.
Pharmatel Fresenius Kabi changes name to Fresenius Kabi Australia.
Fresenius Kabi Australia launches SMOFlipid®, a new lipid emulsion parenteral nutrition product.